Ludwig N. Hantson
Presently, Ludwig N. Hantson holds the position of Chief Executive Officer & Director at Alexion Pharmaceuticals, Inc. Dr. Hantson is also on the board of Hologic, Inc. and Biotechnology Innovation Organization.
In the past Dr. Hantson occupied the position of President-Pharma Canada at Novartis AG and Chief Executive Officer-Pharma North America at Novartis Pharmaceuticals Corp. (a subsidiary of Novartis AG), President-BioScience Division at Baxter International, Inc. Chief Executive Officer of Synovis Life Technologies, Inc. and President at Baxter BioScience Corp. (both are subsidiaries of Baxter International, Inc.), Principal at Johnson & Johnson, President, Chief Executive Officer & Director at Baxalta, Inc. and Principal at Smith & Nephew NV.
Dr. Hantson received a doctorate and a graduate degree from Université Catholique de Louvain.
|12/16/2020||13,059||Derivative/Non-derivative trans. at $157.96 per share.||2,062,800|
|12/16/2020||72,533||Derivative/Non-derivative trans. at $157.96 per share.||11,457,313|
|12/16/2020||162,707||Award at $0 per share.||0|
|03/30/2020||3,202||Derivative/Non-derivative trans. at $85.43 per share.||273,547|
|03/02/2020||8,406||Derivative/Non-derivative trans. at $90.54 per share.||761,080|
|02/28/2020||44,201||Award at $0 per share.||0|
|02/07/2020||12,771||Derivative/Non-derivative trans. at $102.97 per share.||1,315,030|
|02/28/2019||37,198||Award at $0 per share.||0|
|02/28/2019||4,043||Derivative/Non-derivative trans. at $132.92 per share.||537,396|
|02/07/2019||13,015||Derivative/Non-derivative trans. at $119.57 per share.||1,556,204|
|12/31/2018||3,244||Disposition at $95.85 per share.||310,938|
|02/28/2018||35,760||Award at $0 per share.||0|
|02/08/2018||13,245||Disposition at $116.31 per share.||1,540,526|
|02/06/2018||95,253||Award at $0 per share.||0|
|01/02/2018||2,553||Disposition at $121.63 per share.||310,522|
|06/14/2017||10,000||Acquisition at $116.72 per share.||1,167,200|
|03/29/2017||28,725||Award at $0 per share.||0|